Ambulero’s Gene Therapy Candidate AMB-301 Granted U.S. Orphan Drug Designation for Treatment of Severe Vascular Disease

MIAMI, Oct. 19 (Korea Bizwire) — Ambulero Inc., a biotechnology company (“Ambulero” or the “Company”) developing new cell and gene therapy treatments for patients suffering from severe vascular disease, today announced that the U.S. FDA’s Office For Orphan Products Development (OOPD) granted the company’s request for orphan drug status for its gene therapy candidate, AMB-301, [...]